{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T17:03:52Z","timestamp":1774976632500,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82202323"],"award-info":[{"award-number":["82202323"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82472740"],"award-info":[{"award-number":["82472740"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-026-04029-0","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:16:24Z","timestamp":1772115384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory study of olaparib combined with intravesical perfusion in the treatment of secondary bladder cancer after kidney transplantation: preliminary observations and discussion"],"prefix":"10.1186","volume":"31","author":[{"given":"Sheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoqiang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yacong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"10","key":"4029_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1159\/000510616","volume":"51","author":"R Machhi","year":"2020","unstructured":"Machhi R, Mandelbrot DA, Al-Qaoud T, Astor BC, Parajuli S. Characteristics and graft survival of kidney transplant recipients with renal cell carcinoma. Am J Nephrol. 2020;51(10):777\u201385.","journal-title":"Am J Nephrol"},{"key":"4029_CR2","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.biopha.2018.01.094","volume":"99","author":"Y Chen","year":"2018","unstructured":"Chen Y, Du H. The promising PARP inhibitors in ovarian cancer therapy: from olaparib to others. Biomed Pharmacother. 2018;99:552\u201360.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"4029_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"4029_CR4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620\u201331.","journal-title":"Lancet Oncol"},{"issue":"18","key":"4029_CR5","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708.","journal-title":"N Engl J Med"},{"issue":"9","key":"4029_CR6","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/TP.0b013e3181a238f6","volume":"87","author":"Y Miao","year":"2009","unstructured":"Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation. 2009;87(9):1347\u201359.","journal-title":"Transplantation"},{"issue":"2","key":"4029_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.transproceed.2016.11.039","volume":"49","author":"C Demirdag","year":"2017","unstructured":"Demirdag C, Citgez S, Talat Z, Onal B. Management of Bladder Cancer After Renal Transplantation. Transplant Proc. 2017;49(2):293\u20136.","journal-title":"Transplant Proc"},{"issue":"4","key":"4029_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.urology.2012.11.035","volume":"81","author":"D Prabharasuth","year":"2013","unstructured":"Prabharasuth D, Moses KA, Bernstein M, Dalbagni G, Herr HW. Management of bladder cancer after renal transplantation. Urology. 2013;81(4):813\u20139.","journal-title":"Urology"},{"issue":"10","key":"4029_CR9","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1016\/j.transproceed.2014.06.075","volume":"46","author":"S Medani","year":"2014","unstructured":"Medani S, O\u2019Kelly P, O\u2019Brien KM, Mohan P, Magee C, Conlon P. Bladder cancer in renal allograft recipients: risk factors and outcomes. Transplant Proc. 2014;46(10):3466\u201373.","journal-title":"Transplant Proc"},{"key":"4029_CR10","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241245283","volume":"16","author":"N Abbas","year":"2024","unstructured":"Abbas N, Chehade L, Shamseddine A. Personalized treatment with PARP inhibitors in advanced urothelial carcinoma: a case report and literature review. Ther Adv Med Oncol. 2024;16:17588359241245283.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"4029_CR11","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2022.09.025","volume":"83","author":"F Vignani","year":"2023","unstructured":"Vignani F, Tambaro R, De Giorgi U, Giannatempo P, Bimbatti D, Carella C, et al. Addition of Niraparib to best supportive care as maintenance treatment in patients with advanced urothelial carcinoma whose disease did not progress after first-line platinum-based chemotherapy: the Meet-URO12 randomized phase 2 trial. Eur Urol. 2023;83(1):82\u20139.","journal-title":"Eur Urol"},{"key":"4029_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00264","volume":"2","author":"RF Sweis","year":"2018","unstructured":"Sweis RF, Heiss B, Segal J, Ritterhouse L, Kadri S, Churpek JE, et al. Clinical activity of Olaparib in urothelial bladder cancer with DNA damage response gene mutations. JCO Precis Oncol. 2018;2:1\u20137.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"4029_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(3):540-56.e25.","journal-title":"Cell"},{"issue":"22","key":"4029_CR14","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"key":"4029_CR15","volume":"2017","author":"W Abida","year":"2017","unstructured":"Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017:PO.17.00029.","journal-title":"JCO Precis Oncol"},{"issue":"6330","key":"4029_CR16","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"key":"4029_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.689829","volume":"11","author":"M Turinetto","year":"2021","unstructured":"Turinetto M, Scotto G, Tuninetti V, Giannone G, Valabrega G. The role of PARP inhibitors in the ovarian cancer microenvironment: moving forward from synthetic lethality. Front Oncol. 2021;11:689829.","journal-title":"Front Oncol"},{"issue":"5","key":"4029_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01648-5","volume":"39","author":"B Dong","year":"2022","unstructured":"Dong B, Yang B, Chen W, Du X, Fan L, Yao X, et al. Olaparib for Chinese metastatic castration-resistant prostate cancer: a real-world study of efficacy and gene predictive analysis. Med Oncol. 2022;39(5):96.","journal-title":"Med Oncol"},{"issue":"8","key":"4029_CR19","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"4029_CR20","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-18-4222","volume":"25","author":"Y Park","year":"2019","unstructured":"Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin Cancer Res. 2019;25(18):5584\u201394.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4029_CR21","first-page":"1172","volume":"103","author":"NW Choong","year":"2005","unstructured":"Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. Mayo Clin Exp Cancer. 2005;103(6):1172\u20138.","journal-title":"Mayo Clin Exp Cancer"},{"issue":"2","key":"4029_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000501108","volume":"103","author":"L Aznar Mart\u00ednez","year":"2019","unstructured":"Aznar Mart\u00ednez L, L\u00f3pez Cubillana P, L\u00f3pez Abad A, Vidal Crespo N, G\u00f3mez G\u00f3mez GA. Bacillus Calmette-Gu\u00e9rin in immunosuppressed patient with high-grade nonmuscle invasive bladder carcinoma. Urol Int. 2019;103(2):242\u20134.","journal-title":"Urol Int"},{"issue":"4","key":"4029_CR23","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4081\/aiua.2017.4.272","volume":"89","author":"R Giulianelli","year":"2017","unstructured":"Giulianelli R, Gentile BC, Mirabile G, Albanesi L, Tariciotti P, Rizzo G, et al. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience. Arch Ital Urol Androl. 2017;89(4):272\u20136.","journal-title":"Arch Ital Urol Androl"},{"issue":"6","key":"4029_CR24","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3892\/mco.2015.615","volume":"3","author":"Y Zhu","year":"2015","unstructured":"Zhu Y, Xiao J, Guo Y, Lin J, Zhang L, Tian YE. Chemotherapy for urothelial carcinoma in renal transplantation patients: initial results from a single center. Mol Clin Oncol. 2015;3(6):1387\u201391.","journal-title":"Mol Clin Oncol"},{"issue":"20","key":"4029_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203441","volume":"16","author":"P Demuth","year":"2024","unstructured":"Demuth P, Thibol L, Lemsch A, Potlitz F, Schulig L, Grathwol C, et al. Targeting PARP-1 and DNA damage response defects in colorectal cancer chemotherapy with established and novel PARP inhibitors. Cancers (Basel). 2024;16(20):3441.","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-026-04029-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-026-04029-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:59:01Z","timestamp":1774972741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-026-04029-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4029"],"URL":"https:\/\/doi.org\/10.1186\/s40001-026-04029-0","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been conducted in accordance with the provisions of the World Medical Association's Declaration of Helsinki (2000). This study has obtained approval from the Scientific and Technological Ethics Committee of Tianjin First Central Hospital. We hereby declare that all participants in this study have voluntarily signed the informed consent form after fully understanding the purpose, methods, potential risks, and possible benefits of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"481"}}